Allosteric interactions at adenosine A1 and A3 receptors: New insights into the role of small molecules and receptor dimerization

British Journal of Pharmacology

Volumn 171, Issue 5, 2014, Pages 1102-1113

  Hill, Stephen J ^a   May, Lauren T ^b   Kellam, Barrie ^a   Woolard, Jeanette ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b MONASH UNIVERSITY   (Australia)

Author keywords

adenosine; allosterism; biased signalling; dimerization; GPCR; receptor

Indexed keywords

2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; IMIDAZOQUINOLINAMINE DERIVATIVE; QUINOLINE DERIVATIVE; SODIUM ION; UNCLASSIFIED DRUG;

ALLOSTERISM; BINDING KINETICS; BINDING SITE; DIMERIZATION; DRUG ACTIVITY; DRUG INDICATION; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MODIFICATION; REVIEW; SINGLE CELL ANALYSIS;

ADENOSINE; ALLOSTERISM; BIASED SIGNALLING; DIMERIZATION; GPCR; RECEPTOR;

ALLOSTERIC REGULATION; ANIMALS; HUMANS; LIGANDS; PROTEIN MULTIMERIZATION; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A3;

EID: 84895161057     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12345     Document Type: Review

References (115)

1. 1-receptor agonists for cardiovascular therapies. Purinergic Signal 8: S91-S99.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
3. 1 adenosine receptor enhancer of the negative dromotropic action of adenosine in the guinea-pig heart. J Pharm Exp Ther 266: 611-617.
4. 1 adenosine receptor allosteric enhancers. Bioorg Med Chem 16: 1319-1327.
5. 1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. J Med Chem 52: 4543-4547.
6. Avlani V, May LT, Sexton PM, Christopoulos A, (2004). Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 308: 1062-1072.
7. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, et al. (2003). Beta-arrestin-mediated activation of MPAK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci U S A 100: 11406-11411.
8. 2-adrenoceptor provide evidence for agonist-directed signalling. Mol Pharmacol 64: 1357-1369.
9. Baker JG, Hall IP, Hill SJ, (2004). Temporal characteristics of CRE-mediated gene transcription: requirement for sustained cAMP production. Mol Pharmacol 65: 986-998.
10. 1 adenosine receptor. J Med Chem 46: 794-809.
11. 1 receptor. Eur J Med Chem 39: 855-865.
12. 1 adenosine receptor: influences of acidic and hydroxyl residues in the first four transmembrane domains on ligand binding. Mol Pharmacol 50: 1635-1642.
13. 3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kB signal transduction pathways. Int J Oncol 33: 287-295.
14. 3 adenosine receptor agonists CF101. Int J Mol Med 28: 727-731.
15. Briddon SJ, Gandia J, Amaral OB, Ferre S, Lluis C, Franco R, et al. (2008). Plasma membrane diffusion of G protein-coupled receptor oligomers. Biochim Biophys Acta 1783: 2262-2268.
16. Bruns RF, Fergus JH, (1990). Allosteric enhancement of adenosine-A1-receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharmacol 38: 939-949.
17. 1-receptor binding by 2-amino-3-benzoylthiophenes. Mol Pharmacol 38: 950-958.
18. 3 receptors in protection of isolated human atrial muscle against simulated ischaemia. Cardiovasc Res 36: 52-59.
19. Casadõ V, Barrondo S, Spasic M, Callado LF, Mallol J, Canela E, et al. (2010). Gi protein coupling to adenosine A1-A2A receptor heteromers in human brain caudate nucleus. J Neurochem 114: 972-980.
20. 2-adrenergic receptor complexes with altered G protein coupling and signalling. Cell Signal 25: 736-742.
21. 3 receptors. Science 314: 1792-1795.
22. Chiavegatta T, Cost JVL, Araujo MS, Godinho RO, (2008). Skeletal muscle expresses the extracellular cyclic AMP-adenosine pathway. Br J Pharmacol 153: 1331-1340.
23. 3 selective antagonist. Science 330: 1091-1095.
24. Christopoulos A, Kenakin T, (2002). G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54: 323-374.
25. 2 receptors with an 'infinite dilution' procedure. Biochem Pharmacol 53: 795-800.
26. 2- adrenergic receptor. Nature 477: 611-615.
27. Ciruela F, Saura C, Canela EI, Mallol J, Lluis C, Franco R, (1996). Adenosine deaminase affects ligand-induced signalling by interacting with cell surface adenosine receptors. FEBS Lett 380: 219-223.
28. 1 adenosine receptor activation promotes angiogenesis and release of VEGF from monocytes. Circ Res 101: 1130-1138.
29. 3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol 226: 2438-2447.
30. 1 adenosine receptor to different heterotrimeric G-proteins: evidence for agonist-specific G-protein activation. Br J Pharmacol 143: 705-714.
31. Corriden R, Insel PA, (2012). New insights regarding the regulation of chemotaxis by nucleotides, adenosine and their receptors. Purineric Signal 8: 587-598.
32. 3-receptors in neutrophil microdomains promote the formation of bacteria-tethering cytonemes. EMBO Rep 14: 726-732.
33. 2A-R heteromers coupled to Gs and Gi/o proteins modulate GABA transport into astrocytes. Purinergic Signal 9: 433-449.
34. Dowling MR, Charlton SJ, (2006). Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor. Br J Pharmacol 148: 927-937.
35. Du L, Gao ZG, Nithipatikom K, Ijzerman AP, van Veldhoven JPD, Jacobson KA, et al. (2012). Protection from myocardial ischaemia/reperfusion injury by a positive allosteric modulator of the A3 adenosine receptor. J Pharmacol Exp Ther 340: 210-217.
36. Dubey RK, Gillespie DG, Mi Z, Jackson EK, (2001). Endogenous cyclic AMP-adenosine pathway regulates cardiac fibroblast growth. Hypertension 37: 1095-1100.
37. 5 muscarinic receptor subtypes. Biochem Pharmacol 42: 1927-1932.
38. 3 adenosine receptor agonists. Drug Discov Today 17: 359-366.
39. Franco R, Martinez-Pinilla E, Ricobaraza A, McCormick PJ, (2013). Challenges in the development of heteromer-GPCR-based drugs. Prog Mol Biol Transl Sci 117: 143-162.
40. Fredholm BF, Ijzerman AP, Jacobson KA, Linden J, Muller CE, (2011). International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 63: 1-34.
41. 3 adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Mol Pharmacol 60: 1057-1063.
42. Gao ZG, Kim SG, Soltysiak KA, Melman N, Ijzerman AP, Jacobson KA, (2002). Selective allosteric enhancement of agonist binding and function at human A(3) adenosine receptors by a series of imidazoquinoline derivatives. Mol Pharmacol 62: 81-89.
43. 3 adenosine receptor. Mol Pharmacol 63: 1021-1031.
44. Gao ZG, Verziji D, Zweemer A, Ye K, Goblyos A, Ijzerman AP, et al. (2011). Functionally biased modulation of A3- adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers. Biochem Pharmacol 82: 658-668.
45. 3 adenosine receptor. J Pharmacol Exp Ther 319: 1200-1210.
46. 3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin Cancer Res 210: 5895-5901.
47. Göblyös A, Ijzerman AP, (2011). Allosteric modulation of adenosine receptors. Biochim Biophys Acta 1808: 1309-1318.
48. 3 adenosine receptor. J Med Chem 49: 3354-3361.
49. Goedeke A, (2008). cAMP: fuel for extracellular adenosine formation. Br J Pharmacol 153: 1087-1089.
50. 1 receptors mediate local anti-nociceptive effects of acupuncture. Nature Neurosci 13: 883-888.
51. 1 receptor. J Med Chem 54: 8195-8206.
52. 3H-R-PIA binding to the caudate nucleus. J Neurochem 107: 161-170.
53. Gracia E, Farre D, Cortes A, Ferrer-Costa C, Orozco M, Mallol J, et al. (2013). The catalytic site structural gate of adenosine deaminase allosterically modulates ligand binding to adenosine receptors. FASEB J 27: 1048-1061.
54. 1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects. Cephalagia 23: 287-292.
55. Han Y, Moreira IS, Urizar E, Weinstein H, Javitch JA, (2009). Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat Chem Biol 5: 688-695.
56. 3 adenosine receptor activation and gene knock-out in ischemic-reperfused mouse heart. Cardiovasc Res 53: 147-155.
57. 3 receptor. J Med Chem 52: 926-931.
58. Hern JA, Baig AH, Mashanov GI, Birdsall B, Corrie JE, Lazareno S, et al. (2010). Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules. Proc Natl Acad Sci U S A 107: 2693-2698.
59. Hu J, Thor D, Zhou Y, Liu T, Wang Y, McMillin SM, et al. (2012). Structural aspects of M3 muscarinic acetylcholine receptor dimer formation and activation. FASEB J 26: 604-616.
60. Ilien B, Glasser N, Clamme JP, Didier P, Piemont E, Chinnappan R, et al. (2009). Pirenzepine promotes the dimerization of muscarinic M1 receptors through a three-step binding process. J Biol Chem 284: 19533-19543.
61. 2A adenosine receptor bound to an antagonist. Science 322: 1211-1217.
62. Jacobson KA, (2009). Introduction to adenosine receptors as therapeutic targets. Hand Exp Pharmacol 193: 1-24.
63. Jacobson KA, Gao ZG, Göblyös A, Ijzerman AP, (2011). Allosteric modulation of purine and pyrimidine receptors. Adv Pharmacol 61: 187-220.
64. Janusz CA, Berman RF, (1993). The adenosine binding enhancer, PD 81,723, inhibits epileptiform bursting in the hippocampal brain slice. Brain Res 619: 131-136.
65. Kenakin TP, (2009). 7TM receptor allostery: putting numbers to shapeshifting proteins. Trends Pharmacol Sci 30: 460-469.
66. Kenakin TP, (2012). Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br J Pharmacol 165: 1659-1669.
67. Keov P, Sexton PN, Christopoulos A, (2010). Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology 60: 24-35.
68. 1-adenosine receptor: a review. Drug Discov Today: Technol 10: e285-e296.
69. 1 receptors in naïve and chronic epileptic rats. Epilepsia 53: 1978-1986.
70. van der Klein PAM, Kourounakis AP, IJzerman AP, (1999). Allosteric modulation of the adenosine A1 receptor: synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding. J Med Chem 42: 3629-3635.
71. Knapp K, Zebisch M, Pippel J, El-Tayeb A, Muller CE, Srater N, (2012). Crystal structure of the human ecto-5′-nucleotidase (CD73): insights into the regulation of purinergic signaling. Structure 20: 2161-2173.
72. Kostenis E, Mohr K, (1996). Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. Trends Pharmacol Sci 17: 280-283.
73. 1 receptors. Drug Dev Res 49: 227-237.
74. Kuszak AJ, Pitchiaya S, Anand JP, Mosberg HI, Walter NG, Sunahara RK, (2009). Purification and functional reconstitution of monomeric mu-opioid receptors: allosteric modulation of agonist binding by Gi2. J Biol Chem 284: 26732-26741.
75. 1 receptor ligands? Purinergic Signal 9: 91-100.
76. Lazareno S, Birdsall NJ, (1995). Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48: 362-378.
77. 3 receptors. Am J Physiol Renal Physiol 278: F380-F387.
78. 1 adenosine receptor activation inhibits inflammation, necrosis, and apoptosis after renal ischemia-reperfusion injury in mice. J Am Soc Nephrol 15: 102-111.
79. Lee NH, El-Fakahany EE, (1991). Allosteric antagonists of the muscarinic acetylcholine receptor. Biochem Pharmacol 42: 199-205.
80. Limbird LE, Meyts PD, Lefkowitz RJ, (1975). Beta-adrenergic receptors: evidence for negative cooperativity. Biochem Biophys Res Commun 64: 1160-1168.
81. Liu W, Chun E, Thompson AA, Chubukov P, Xu F, Vet K, (2012). Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337: 232-236.
82. 2-adrenoceptor agonist mediating cyclic AMP accumulation in a neuronal cell line. Br J Pharmacol 110: 619-626.
83. 3 adenosine receptor is highly expressed in tumor vs. normal cells: potential target for tumor growth inhibition. Clin Cancer Res 10: 4472-4479.
84. 1 adenosine receptors. J Neural Transm 117: 1269-1277.
85. 1 adenosine receptor overexpression increases myocardial resistance to ischaemia. Proc Natl Acad Sci 94: 6541-6546.
86. May LT, Leach K, Sexton PM, Christopoulos A, (2007). Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47: 1-51.
87. 3 receptor pharmacology by the food dye Brilliant Black BN: evidence for allosteric interactions. Mol Pharmacol 77: 678-686.
88. May LT, Self TJ, Briddon SJ, Hill SJ, (2010b). The effect of allosteric modulators on the kinetics of agonist-G protein-coupled receptor interactions in single living cells. Mol Pharmacol 78: 511-523.
89. 3 receptor homodimers: quantification using single cell ligand binding kinetics. FASEB J 25: 3465-3476.
90. Meno JR, Higashi H, Cambray AJ, Zhou J, D'Ambrosio R, Winn HR, (2003). Hippocampal injury and neurobehavioural deficits are improved by PD 81723 following hyperglycemic cerebral ischemia. Exp Neurol 183: 188-196.
91. 3 adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. Neoplasia 11: 1064-1073.
92. 1 adenosine receptors on post-ischaemic cardiac function and expression of adenosine receptor subtypes. Am J Physiol Heart Circ Physiol 291: H1875-h1882.
93. Muller CE, Jacobson KA, (2011). Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Et Biophys Acta 1808: 1290-1308.
94. 1 receptor allosteric enhancers. Bioorg Med Chem 14: 2358-2365.
95. 1 adenosine receptor allosteric enhancer PD-81723 protects against renal ischaemia-reperfusion injury. Am J Physiol Renal Physiol 303: F721-F732.
96. 1 receptor in activation and allosteric modulation. Biochem Pharmacol 84: 76-87.
97. Pisterzi LF, Jansma DB, Georgiou J, Woodside MJ, Chou JT, Angers S, et al. (2010). Oligomeric size of the m2 muscarinic receptor in live cells as determined by quantitative fluorescence resonance energy transfer. J Biol Chem 285: 16723-16738.
98. 2 adrenergic receptor-Gs protein complex. Nature 477: 549-555.
99. 1 adenosine receptor. J Med Chem 51: 5875-5879.
100. Roth BL, Marshall FH, (2012). NOBEL 2012 chemistry: studies of a ubiquitous receptor family. Nature 492: 57.
101. 3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol Chem 275: 4429-4434.
102. Smith NJ, Milligan G, (2010). Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes. Pharmacol Rev 62: 701-725.
103. 1 receptor activation. Mol Pain 6: 20.
104. Springael JY, Le Minh PN, Urizar E, Costagliola S, Vassart G, Parmentier M, (2006). Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers. Mol Pharmacol 69: 1652-1661.
105. Street SE, Zylka MJ, (2011). Emerging roles for ectonucleotidases in pain-sensing neurons. Neuropsychopharmacol 36: 358.
106. 2 receptor. Biochem Biophys Res Commun 351: 559-565.
107. Swaminath G, Xiang Y, Lee TW, Steenhuis J, Parnot C, Kobilka BK, (2004). Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states. J Biol Chem 279: 686-691.
108. 1 receptor agonist capadenoson in male patients with stable angina. Clin Res Cardiol 101: 585-591.
109. Tinney FJ, Sanchez JP, Nogas JA, (1974). Synthesis and pharmacological evaluation of 2,3-dihydro-1H-thieno[2,3-e][1,4]diazepines. J Med Chem 17: 624-630.
110. Uematsu M, Gaudette GR, Laurikka JO, Levitsky S, McCully JD, (1998). Adenosine-enhanced ischaemic preconditioning decreases infarct size in the regional ischaemic sheep heart. Ann Thorac Surg 66: 382-387.
111. Urizar E, Yano H, Kolster R, Galés C, Lambert N, Javitch JA, (2011). CODA-RET reveals functional selectivity as a result of GPCR heteromerization. Nat Chem Biol 7: 624-630.
112. 1 receptorallosteric modulators. Mol Pharm 78: 444-455.
113. Whalen EJ, Rajagopal S, Lefkowitz RJ, (2011). Therapeutic potential of β-arrestin and G protein-biased agonists. Trends Mol Med 17: 126-139.
114. Williams C, Hill SJ, (2009). GPCR signalling: understanding the pathway to successful drug discovery. Methods Mol Biol 552: 39-50.
115. 2A adenosine receptor. Science 332: 322-327.